CHANGES IN OVERACTIVE BLADDER SYMPTOMS AFTER DISCONTINUATION OF SUCCESSFUL 3-MONTH TREATMENT WITH AN ANTIMUSCARINIC AGENT: A PROSPECTIVE TRIAL-Reference-Cited by-同舟云学术

CHANGES IN OVERACTIVE BLADDER SYMPTOMS AFTER DISCONTINUATION OF SUCCESSFUL 3-MONTH TREATMENT WITH AN ANTIMUSCARINIC AGENT: A PROSPECTIVE TRIAL

Published:2005-07 Issue:1 Volume:174 Page:201-204
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

CHOO MYUNG-SOO¹,SONG CHERYN¹,KIM JIN HYUN¹,CHOI JONG-BO¹,LEE J.I. YOUL¹,CHUNG BYUNG SOO¹,LEE KYU SUNG¹

Affiliation:

1. From the Department of Urology, Asan Medical Center, University of Ulsan College of Medicine (M-SC, CS), Samsung Medical Center, Sungkyunkwan University School of Medicine (JHK, KSL), Ajou University Hospital (J-BC), Holy Family Hospital, Catholic University of Korea (JYL) and Hallym University Sacred-Heart Hospital (BSC), Seoul, Korea

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference13 articles.

1. Diagnosis and treatment of the overactive bladder

2. Long-Term Safety, Tolerability and Efficacy of Extended-Release Tolterodine in the Treatment of Overactive Bladder

3. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

4. Management of Overactive Bladder

5. Antimuscarinics for treatment of overactive bladder

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. On-demand use of fesoterodine: a new paradigm for extended release antimuscarinics;International Urogynecology Journal;2022-06-06

2. Overactive bladder symptoms recurrence after sudden versus gradual weaning of Solifenacin;African Journal of Urology;2020-12

3. Overactive bladder medication: Persistence, drug switching, and reinitiation;Neurourology and Urodynamics;2020-09-28

4. THE PHARMACOTHERAPY TIME-TO-EFFECT OF OVERACTIVE BLADDER MEDICATIONS AND TREATMENT DURATION;Acta Poloniae Pharmaceutica - Drug Research;2020-06-29

5. The probability of re-treatment after discontinuation of a 3-month versus a 6-month course of solifenacin for female overactive bladder: A prospective randomized controlled study;Maturitas;2019-08